<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530799</url>
  </required_header>
  <id_info>
    <org_study_id>IAPAFLU</org_study_id>
    <nct_id>NCT04530799</nct_id>
  </id_info>
  <brief_title>Prospective Observational Trial of IAPA</brief_title>
  <acronym>IAPAFLU</acronym>
  <official_title>Influenza-associated Pulmonary Aspergillosis (IAPA) in ICU Patients With Severe Influenza: Incidence and Host- and Pathogen Related Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective multi-center observational study to assess the incidence of&#xD;
      influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and&#xD;
      pathogen related risk factors for IAPA in EORTC negative ICU patients with severe influenza.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Invasive pulmonary aspergillosis was shown to be a complication of severe influenza&#xD;
      infections in immunocompromised patients as well as in immunocompetent patients and is&#xD;
      associated with a high mortality. Antifungal prophylaxis might prevent influenza-associated&#xD;
      pulmonary aspergillosis (IAPA) and thus might improve the outcome in patients with severe&#xD;
      influenza. However, clinical related risk factors should be identified to assess whether a&#xD;
      patient will benefit from antifungal prophylaxis. This prospective multi-center observational&#xD;
      study will assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU&#xD;
      patients in 12 ICUs in The Netherlands, Belgium and France over 4 influenza seasons. The&#xD;
      secondary objective of this study is to identify host- and pathogen related risk factors for&#xD;
      IAPA in EORTC negative ICU patients with severe influenza. Patients aged 18 or older admitted&#xD;
      to the intensive care unit (ICU) during the inclusion period due severe influenza without&#xD;
      classic risk factors defined by the EORTC will be included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of IAPA-infection at ICU discharge</measure>
    <time_frame>from date of admission in ICU assessed up to ICU discharge, approximately 21 days</time_frame>
    <description>The diagnosis of IAPA will be made by the treating physician, according to a strict case definition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to IAPA diagnosis</measure>
    <time_frame>from date of admission in ICU assessed up to ICU discharge, approximately 21 days</time_frame>
    <description>The diagnosis of IAPA will be made by the treating physician, according to a strict case definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>from date of admission in ICU assessed up to ICU discharge, approximately 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>from date of admission in hospital assessed up to hospital discharge, approximately 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>up to ICU discharge, approximately 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>from date of admission in hospital assessed up to hospital discharge, approximately 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Influenza With Pneumonia</condition>
  <condition>Pulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>IAPA+</arm_group_label>
    <description>Influenza patients who develop IAPA during ICU admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IAPA-</arm_group_label>
    <description>Influenza patients admitted to the ICU not developing IAPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Identification of biomarkers for IAPA via patient sampling</intervention_name>
    <description>Blood, BAL, microbiome</description>
    <arm_group_label>IAPA+</arm_group_label>
    <arm_group_label>IAPA-</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target patient population is the EORTC-negative population of critically ill influenza&#xD;
        patients at ICU. Patient identification will rely on daily review of ICU patients with&#xD;
        respiratory virus panels ordered in the previous 24 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a PCR-positive respiratory virus panel (RVP) result for influenza within&#xD;
             96 hours before or 48 hours after ICU admission.&#xD;
&#xD;
          -  Patients who require ICU admission for more than 24 hours for severe influenza.&#xD;
&#xD;
          -  Patients who have respiratory distress (respiratory rate &gt;= 25x/minute and paO2/fiO2 &lt;&#xD;
             300 with or without bilateral infiltrates) as the main reason for ICU admission.&#xD;
&#xD;
          -  Patients who do not have an EORTC host factor.&#xD;
&#xD;
          -  Patients who are at least 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with age &lt; 18 years as extensive sampling is required&#xD;
&#xD;
          -  Expected survival on ICU admission â‰¤ 48h&#xD;
&#xD;
          -  Patients that are being treated actively with antifungal agents for invasive&#xD;
             aspergillosis.&#xD;
&#xD;
          -  Patients or their legal representatives who did not sign the informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost Wauters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joost Wauters, MD, PhD</last_name>
    <phone>+32-16-344275</phone>
    <email>joost.wauters@uzleuven.be</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Influenza-associated pulmonary aspergillose</keyword>
  <keyword>Invasive Pulmonary Aspergillosis</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Respiratory tract infections</keyword>
  <keyword>Fungal Lung Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

